We announce the return of our 8th annual
RNA Therapeutics conference to London on the 22nd - 23rd of February 2017. Technology in RNA interference, oligonucleotides and mRNA has revolutionised the way infectious disease, cancer and neurological disorders are treated. It is now possible to target previously 'un-druggable' sites, therefore expanding the range of therapeutics that selectively silence genes before the disease develops.
AstraZeneca has added another $140 million to its $1.2 billion investment into Moderna Therapeutics' mRNA technology. Consequently continued collaboration between pharmaceutical giants and innovative biotechnology companies, has created considerable funding and buzz around RNA research.
The main challenge in
RNA therapeutics continues to be the delivery of RNA based drugs to target sites outside the liver. Join us in exploring the different delivery systems in use and in development such as transportation with nanoparticles and the ability to enhance drug stability.
We will be reviewing clinical trial updates in RNA- based therapeutics and discussing the current regulations involved in getting drug approval. Learn about the main developments currently shaping the industry and how best to tackle challenges facing RNA therapeutics.
Benefits of Attending
- Overcome challenges in regulation and maximise therapeutics manufacturing by seeing BioNTech up-scale personalized RNA Nanomedicines in cancer Vaccines.
- Gain practical skills from MiNA Therapeutics on RNA activation and the results of their clinical trials. They will be discussing the impact saRNA is having on patients suffering from liver disease- discover how you too can strengthen your approach to clinical trials.
- AstraZeneca will be Exploring emerging antisense oligonucleotide drugs and ways in you can improve drug delivery and optimise clinical results.
- Hear from GSK on the progress of their 5 year IMI COMPACT project and the results of their collaboration with other pharmaceutical companies into the optimisation of oligonucleotide drug delivery.
- Find out how to strategically plan and execute a successful clinical study with an exclusive update from Exicure on their unique nucleic acid based topical treatment for psoriasis.
Plus An Interactive Half-Day Pre-Conference Workshop | Tuesday 21st February 2017
Precision Nano-therapeutics: Minding the gap in delivery from preclinical studies to clinical successLeader: Professor Andrew David Miller, Professor of Organic Chemistry & Chemical Biology, CSO, King’s College London, KP Therapeutics Ltd
08.30am – 12.30pm
Speakers
- Amotz Shemi, CEO, Silenseed
- Andrew Miller, CSO, KP Therapeutics Ltd
- Bo Rode Hansen, Director, Technology and Partnered Discovery, Santaris Pharma A/S
- David Giljohann, CEO, Exicure Inc.
- Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech AG
- Jeffrey Ulmer, Head Preclinical R&D, GSK
- John Johnston, Clinical Assessor, Biologicals & Biotechnology Unit, MHRA
- Mark Chapman, Partner, Carpmaels & Ransford
- Mark Edbrooke, Senior Principal Scientist, AstraZeneca
- Nagy Habib, Professor Department of Surgery & Cancer and Co-founder MiRNA Therapeutics, Imperial College London
- Nicole meisner-kober, Senior Investigator, Novartis Institutes for Biomedical Research
- Sanyogitta Puri, Associate Prinicipal Scientist, AstraZeneca
- Shai Erlich, VP, Pharmaceutical Development, Quark Biotech Inc
- Steffen Panzner, Managing Director, Lipocalyx
- Steve Hood, Director, Scinovo, GSK
- Sudhir Agrawal, President & C S O, Idera Pharmaceuticals
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under donwloads at the right side of the page.
Venue
Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK
Venue
Copthorne Tara HotelScarsdale Place
Kensington
London, United Kingdom
